<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796131</url>
  </required_header>
  <id_info>
    <org_study_id>RDX5791-102</org_study_id>
    <nct_id>NCT02796131</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Different Multiple Dose Regimens of RDX5791 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardelyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardelyx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the
      safety, tolerabiltiy, and pharmacodynamics of different multiple dose regimens of RDX5791 in
      healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The starting doses for this study are based on the results from the multiple ascending-dose
      study performed on RDX5791 (Protocol RDX5791-101). Subjects will be screened within 3 weeks
      of check in to the CPU. Each cohort of 15 subjects (12 RDX5791, 3 placebo) will check in to
      the CPU on Day -5 before dinner. Each subject will receive a diet standardized for Na+
      content while in the CPU. Subjects will receive doses of RDX5791 with approximately 240 mL of
      non-carbonated water on Days 1 to 7 (just prior to meals, depending on QD, bid, or tid
      regimens). Subjects will be provided standardized meals within 10 minutes after dosing. Doses
      can be administered with breakfast, lunch, or dinner.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of different dosing regimens of RDX5791</measure>
    <time_frame>7 Days</time_frame>
    <description>Safety assessments will be based on adverse events, clinical laboratory tests, vital signs, ECG, and physical exams.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of different dosing regimens of RDX5791</measure>
    <time_frame>7 Days</time_frame>
    <description>Pharmacodynamics of different dosing regimens of RDX5791 will be assessed by bowel movement timing, consistency, frequency, and by urine and stool sodium (Na+) excretion.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>30 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg of RDX5791 administered twice daily PO (60 mg total dose/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg tid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg of RDX5791 administered three times daily PO (90 mg total dose/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg of RDX5791 administered two times daily (120 mg total dose/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg of RDX5791 administered two times daily (30 mg total dose/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg of RDX5791 administered once daily (30 mg total dose/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalating dose bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg or 30 mg or 45 mg of RDX5791 administered two times daily (30, 60, or 90 mg total dose/day respectively). The stopping criteria for the dose escalation is based on Bristol Stool Score and AEs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg bid with psyllium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg of RDX5791 administered two times daily (60 mg total dose/day) with psyllium taken up to three times per day (maximum of 15 g psyllium/day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDX5791</intervention_name>
    <arm_group_label>30 mg bid</arm_group_label>
    <arm_group_label>30 mg tid</arm_group_label>
    <arm_group_label>60 mg bid</arm_group_label>
    <arm_group_label>15 mg bid</arm_group_label>
    <arm_group_label>30 mg QD</arm_group_label>
    <arm_group_label>Escalating dose bid</arm_group_label>
    <arm_group_label>30 mg bid with psyllium</arm_group_label>
    <other_name>Tenapanor</other_name>
    <other_name>AZD1722</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>30 mg bid</arm_group_label>
    <arm_group_label>30 mg tid</arm_group_label>
    <arm_group_label>60 mg bid</arm_group_label>
    <arm_group_label>15 mg bid</arm_group_label>
    <arm_group_label>30 mg QD</arm_group_label>
    <arm_group_label>Escalating dose bid</arm_group_label>
    <arm_group_label>30 mg bid with psyllium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index between 18 and 29.9 kg/m², inclusive

          -  No clinically significant abnormalities in medical history

          -  Females must be non-pregnant, non-lactating, and either postmenopausal for at least 12
             months or have agreed to use an effective form of contraception from the time of
             signing the informed consent until 45 days after end of study

          -  Men must be either sterile, abstinent, or agreed to use an approved method of
             contraception from check-in until 45 days after final study visit

        Exclusion Criteria:

          -  Diagnosis or treatment of any clinically symptomatic biochemical or structural
             abnormality of the GI tract

          -  Any surgery on the small intestine or colon, excluding appendectomy

          -  Loose stools (Bristol Stool Form Score of 6 or 7) ≥2 days in the past 7 days

          -  Hepatic dysfunction ([ALT] or [AST]) &gt;1.5 times the upper limit of normal or renal
             impairment

          -  Any evidence of or treatment of malignancy, excluding non-melanomatous malignancies of
             the skin

          -  Use of diuretic medications, medications that are known to affect stool consistency
             and/or GI motility

          -  Use of an investigational agent within 30 days prior to Day -2

          -  Positive virology, alcohol, or drugs of abuse test during screening

          -  Use of any prescription medication within 7 days before admission to the CPU

          -  Have had significant blood loss (&gt;450 mL) or have donated 1 or more units of blood or
             plasma within 8 weeks prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P. Rosenbaum, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Ardelyx, Inc.</affiliation>
  </overall_official>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Healthy</keyword>
  <keyword>Pharmacodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psyllium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

